Nav: Home

New drug combinations help patients whose HIV develops resistance after several different treatments

July 08, 2002

BARCELONA, Spain--Cocktails of anti-AIDS drugs have dramatically increased survival of individuals infected with HIV. But the virus often develops resistance to the drugs in people who previously have taken multiple combinations of the medications.

Now a multi-center, randomized, and placebo-controlled trial of 481 people infected with HIV, co-chaired by Dr. Scott Hammer of Columbia University and Dr. John Mellors of the University of Pittsburgh, shows that giving patients a new combination of drugs, which includes two protease inhibitors rather than one, can reduce the virus load in a substantial proportion of patients who already had taken several anti-HIV drugs.

"Control of virus load levels in the blood leads to an improved immune system and a greater period of health, delaying the opportunistic infections and death associated with HIV infection," says Dr. Hammer. Dr. Hammer is professor of medicine, Harold C. Neu Professor of Infectious Diseases, professor of epidemiology in the Mailman School of Public Health, and chief of the Division of Infectious Diseases at Columbia Presbyterian Medical Center of NewYork-Presbyterian Hospital. Dr. Mellors is professor of medicine, chief of the Division of Infectious Diseases, and director of the HIV/AIDS program at the University of Pittsburgh School of Medicine

The study results are being published online July 6 by the Journal of the American Medical Association to coincide with the International AIDS Conference in Barcelona, Spain. The study was supported by the National Institute of Allergy and Infectious Diseases-sponsored Adult AIDS Clinical Trials Group (ACTG).

In the ACTG 398 study, which took place at 31 participating medical centers in the United States, patients were split into four groups, each taking the protease inhibitor, amprenavir, and either a placebo or a second protease inhibitor (saquinavir, indinavir, or nelfinavir). A protease inhibitor interferes with an enzyme HIV uses to reproduce itself.

All participants also received drugs that act on the HIV reverse transcriptase enzyme: abacavir, a nucleoside reverse transcriptase inhibitor; efavirenz, a non-nucleoside reverse transcriptase inhibitor; and adefovir dipivoxil, a nucleotide reverse transcriptase inhibitor. Reverse transciptase is another essential enzyme the virus uses to reproduce itself in human cells. These drugs had not been taken before by the patients.

After 24 weeks, the investigators found that 31 percent of these antiretroviral-experienced patients with moderately advanced immunodeficiency could significantly lower their virus counts to below "detectable levels" with regimens containing four or five new drugs.

"The overall response rate in the study was modest but resistance in this experienced population is a difficult problem to overcome and we set a high standard of virus suppression (i.e., a viral load less than 200 HIV/RNA copies/milliliter) to show success," Dr. Hammer says.

On average, though, the patients showed more than a 90 percent reduction in their blood viral load--although they may not have achieved a 200 RNA copy/ml level. "The decrease should be associated with improved health," Dr Hammer says.

Certain subgroups of patients, however, did better than others: patients who took two protease inhibitors and those who had never taken a non-nucleoside drug before the study. Patients who had a higher-than-usual level of sensitivity to the non-nucleoside inhibitor, efavirenz, termed hypersusceptibility, had a better response than those with the usual level of sensitivity to the drug.

"The study results have clear implications for HIV-infected individuals who are planning their long-term treatment approach," Dr. Hammer says. "Reserving potent classes of drugs, if possible, rather than using all of them in a cocktail during first- and second-line treatments should improve the long-term response rates of patients to anti-HIV drugs."

The study also points to the continuing need for new types of drugs that have activity against HIV strains resistant to older drugs. "There are promising drugs on the horizon that should move the field closer to the goal of long-term viral suppression and clinical well being over many years, if not decades," Dr. Hammer says.

Columbia University Medical Center

Related Hiv Articles:

Defective HIV proviruses reduce effective immune system response, interfere with HIV cure
A new study finds defective HIV proviruses, long thought to be harmless, produce viral proteins and distract the immune system from killing intact proviruses needed to reduce the HIV reservoir and cure HIV.
1 in 7 people living with HIV in the EU/EEA are not aware of their HIV status
Almost 30,000 newly diagnosed HIV infections were reported by the 31 European Union and European Economic Area (EU/EEA) countries in 2015, according to data published today by ECDC and the WHO Regional Office for Europe.
Smoking may shorten the lifespan of people living with HIV more than HIV itself
A new study led by researchers at Massachusetts General Hospital finds that cigarette smoking substantially reduces the lifespan of people living with HIV in the US, potentially even more than HIV itself.
For smokers with HIV, smoking may now be more harmful than HIV itself
HIV-positive individuals who smoke cigarettes may be more likely to die from smoking-related disease than the infection itself, according to a new study published in the Journal of Infectious Diseases.
Patients diagnosed late with HIV infection are more likely to transmit HIV to others
An estimated 1.2 million people live with HIV in the United States, with nearly 13 percent being unaware of their infection.
The Lancet HIV: New HIV infections stagnating at 2.5 million a year worldwide
A major new analysis from the Global Burden of Disease 2015 study, published today in The Lancet HIV journal, reveals that although deaths from HIV/AIDS have been steadily declining from a peak in 2005, 2.5 million people worldwide became newly infected with HIV in 2015, a number that hasn't changed substantially in the past 10 years.
NIH scientists discover that defective HIV DNA can encode HIV-related proteins
Investigators from the National Institutes of Health have discovered that cells from HIV-infected people whose virus is suppressed with treatment harbor defective HIV DNA that can nevertheless be transcribed into a template for producing HIV-related proteins.
Study examines risk of HIV transmission from condomless sex with virologically suppressed HIV infection
Among nearly 900 serodifferent (one partner is HIV-positive, one is HIV-negative) heterosexual and men who have sex with men couples in which the HIV-positive partner was using suppressive antiretroviral therapy and who reported condomless sex, during a median follow-up of 1.3 years per couple, there were no documented cases of within-couple HIV transmission, according to a study appearing in the July 12 issue of JAMA, an HIV/AIDS theme issue.
HIV vaccine design should adapt as HIV virus mutates
Researchers from UAB, Emory and Microsoft demonstrate that HIV has evolved to be pre-adapted to the immune response, worsening clinical outcomes in newly infected patients.
Charlie Sheen's HIV disclosure may reinvigorate awareness, prevention of HIV
Actor Charlie Sheen's public disclosure in November 2015 that he has the human immunodeficiency virus (HIV) corresponded with the greatest number of HIV-related Google searches ever recorded in the United States, according to an article published online by JAMA Internal Medicine.

Related Hiv Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...